Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPRG.L Regulatory News (PRG)

  • There is currently no data for PRG

Trading Update

10 Aug 2007 08:30

Premier Research Group10 August 2007 For immediate release 10 August 2007 Premier Research Group plc Trading update The Board of Premier Research Group plc (AIM: PRG) ('Premier Research','Company' or 'Group'), the international pharmaceutical services group, hasnoted the recent fall in its share price and whilst recognising the volatilityin the UK stock market generally, provides the following update. Following the announcement on 13 July 2007 of the acquisitions of ARS andD-Target and the pre-close update, Premier Research is pleased to announce thatthe integration of the new businesses is progressing well. The data managementgroups in the US are working well together and the integration of the medicaldevices capability within the International division is progressing to plan.Several cross-selling opportunities have already begun to develop across theGroup. New order intake across the Group remains strong and the backlog of orderscontinues to grow with over £8 million of new orders having been won since 1July, improving still further the longer term visibility. As the Company movesinto its traditionally busiest season, with over 80% of full year expectationsalready booked or scheduled for delivery, the Board maintains confidence ofachieving its consensus forecasts for the full year. Enquiries: Premier Research Group plc Tel: 01344 752375Dr Simon Yaxley, Chief Executive Officerwww.premier-research.com Buchanan Communications Tel: 020 7466 5000Lisa Baderoon, Rebecca Skye Dietrich Evolution Securities Tel: 020 7071 4300Simon Leathers This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Oct 20078:31 amRNSRule 8.3- Amendment
31st Oct 20078:31 amRNSRule 8.3 - Premier Research
31st Oct 20078:29 amRNSRule 8.3- Premier Research
31st Oct 20078:27 amRNSRule 8.3 - Premier Research
30th Oct 20079:32 amRNSEPT Disclosure
29th Oct 20073:40 pmRNSRule 8.3- (Premier Research)
29th Oct 20078:35 amRNSEPT Disclosure
26th Oct 200712:22 pmRNSRule 8.3- Premier Research Gp
26th Oct 200711:59 amRNSRule 8.3-Premier Research Gp
26th Oct 200710:07 amRNSEPT Disclosure
25th Oct 20073:32 pmRNSRule 8.3- Premier Research Gp
25th Oct 20078:37 amRNSEPT Disclosure
24th Oct 20072:00 pmRNSRule 8.3- Premier Research
24th Oct 20079:45 amRNSEPT Disclosure
23rd Oct 20073:01 pmRNSRule 8.3- Premier Research Gp
23rd Oct 20073:00 pmRNSRule 8.3- premier research
23rd Oct 200711:29 amRNSEPT Disclosure
22nd Oct 20079:07 amRNSEPT Disclosure
19th Oct 20073:26 pmRNSRule 8.3- (Premier Research)
19th Oct 200712:55 pmRNSInterim dividend-Amendment
19th Oct 200710:16 amRNSEPT Disclosure
19th Oct 20077:01 amRNSInterim Dividend
18th Oct 20073:14 pmRNSRule 8.3- Premier Research
18th Oct 20078:20 amRNSEPT Disclosure
18th Oct 20077:02 amRNSInterim Results
17th Oct 200710:08 amRNSEPT Disclosure
16th Oct 200710:23 amRNSEPT Disclosure
16th Oct 200710:11 amRNSNotification of Results
15th Oct 20072:50 pmRNSRule 8.3- Premier Research Gp
15th Oct 20078:57 amRNSEPT Disclosure
12th Oct 200710:59 amRNSRule 8.3- Premier Research Gp
12th Oct 20079:27 amRNSEPT Disclosure
11th Oct 200711:17 amRNSRule 8.3- Premier Research Gp
11th Oct 20079:35 amRNSEPT Disclosure
10th Oct 20072:23 pmRNSRule 8.3- PREMIER RESEARCH
9th Oct 20071:29 pmRNSRule 8.3- Premier Research Gp
9th Oct 20078:23 amRNSEPT Disclosure
8th Oct 20079:48 amRNSEPT Disclosure
5th Oct 200711:57 amRNSRule 8.3- Premier Research
5th Oct 200710:12 amRNSEPT Disclosure
4th Oct 20079:53 amRNSEPT Disclosure
3rd Oct 200712:55 pmRNSEPT Disclosure
2nd Oct 20079:53 amRNSEPT Disclosure
1st Oct 20078:18 amRNSEPT Disclosure
28th Sep 200711:04 amRNSRule 8.3- Premier Research
28th Sep 200710:25 amRNSEPT Disclosure
27th Sep 200712:01 pmRNSRule 8.3- Premier Research Gp
27th Sep 200710:25 amRNSRule 8.3-Premier Research Grp
27th Sep 20079:16 amRNSEPT Disclosure
26th Sep 20079:20 amRNSEPT Disclosure

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.